华丽家族股份有限公司关于现金增资上海海和药物研究开发股份有限公司 暨关联交易的进展公告

Core Viewpoint - The company, Huayi Family Co., Ltd., is investing approximately RMB 299.99 million to subscribe for 63,157,894 new shares of Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. at a price of RMB 4.75 per share, constituting a related party transaction [1][2][6]. Group 1: Transaction Overview - The company signed a subscription agreement on August 10, 2025, to participate in Haihe Pharmaceutical's share issuance, with a total investment not exceeding RMB 300 million [2]. - The company will hold at least 5% of Haihe Pharmaceutical's total shares after the financing is completed [2]. - The company completed the payment of RMB 299,999,996.50 on September 25, 2025, and Haihe Pharmaceutical will proceed with the necessary registration changes [4]. Group 2: Governance and Rights - The company has the right to nominate one observer to the board of Haihe Pharmaceutical, who can attend meetings and provide opinions but does not have voting rights [3]. - The agreement will take effect once all parties have affixed their official seals [3]. Group 3: Strategic Purpose and Impact - The investment aligns with the company's strategy to enhance its core competitiveness and profitability while exploring opportunities in emerging industries [7]. - This strategic financial investment is based on the long-term potential of innovative drugs, aiming to ensure stable operations of the main business while obtaining reasonable financial returns [7]. - The company's financial structure is stable, with a low debt-to-asset ratio, indicating that this investment will not adversely affect its financial and operational status [7].